Metastases drive most cancer-related mortality. So, identifying mutations that are driving cancer growth and that are also present among all metastases of a cancer may be important in disease ...

Please provide your email address to receive an email when new articles are posted on . Patients with myelofibrosis who cleared their mutations 30 days following stem cell transplantation experienced ...

Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis, a German study showed. Disease-free ...

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

The researchers noted that most genomic analyses have traditionally focused on commonly mutated genes, which can pinpoint mutations occurring most frequently but does not account for the extent to ...

Stage III NSCLC: What Are the Treatment Options Today?

Experts share insights on the use chemotherapy and immunotherapy in driver-negative patients, along with the use of PD-L1 inhibitors. Joshua Sabari, MD: Yeah, I couldn’t agree more. I do the exact ...

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance[1-5] Recent guideline updates ...

A study published in the Proceedings of the National Academy of Sciences by scientists from Israel and Ghana shows that an evolutionarily significant mutation in the human APOL1 gene arises not ...